NO321984B1 - Konjugat, fremstilling, samt anvendelse derav - Google Patents

Konjugat, fremstilling, samt anvendelse derav Download PDF

Info

Publication number
NO321984B1
NO321984B1 NO19975435A NO975435A NO321984B1 NO 321984 B1 NO321984 B1 NO 321984B1 NO 19975435 A NO19975435 A NO 19975435A NO 975435 A NO975435 A NO 975435A NO 321984 B1 NO321984 B1 NO 321984B1
Authority
NO
Norway
Prior art keywords
superantigen
see
sea
amino acid
binding
Prior art date
Application number
NO19975435A
Other languages
English (en)
Norwegian (no)
Other versions
NO975435D0 (no
NO975435L (no
Inventor
Mikael Dohlsten
Per Bjork
Per Antonsson
Johan Hansson
Terje Kalland
Lars Abrahmsen
Goran Forsberg
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9601245A external-priority patent/SE9601245D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of NO975435D0 publication Critical patent/NO975435D0/no
Publication of NO975435L publication Critical patent/NO975435L/no
Publication of NO321984B1 publication Critical patent/NO321984B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
NO19975435A 1996-03-29 1997-11-26 Konjugat, fremstilling, samt anvendelse derav NO321984B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9601245A SE9601245D0 (sv) 1996-03-29 1996-03-29 Chimeric superantigens and their use
US08/695,692 US6514498B1 (en) 1996-03-19 1996-08-12 Modified/chimeric superantigens and their use
PCT/SE1997/000537 WO1997036932A1 (en) 1996-03-29 1997-03-26 Modified/chimeric superantigens and their use

Publications (3)

Publication Number Publication Date
NO975435D0 NO975435D0 (no) 1997-11-26
NO975435L NO975435L (no) 1998-01-29
NO321984B1 true NO321984B1 (no) 2006-07-31

Family

ID=26662565

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975435A NO321984B1 (no) 1996-03-29 1997-11-26 Konjugat, fremstilling, samt anvendelse derav

Country Status (20)

Country Link
US (1) US7226595B2 (https=)
EP (1) EP0835266B1 (https=)
JP (1) JP4114951B2 (https=)
AT (1) ATE294818T1 (https=)
AU (1) AU707827B2 (https=)
BR (1) BR9702179A (https=)
CA (1) CA2222757C (https=)
CZ (1) CZ294475B6 (https=)
DE (1) DE69733179T2 (https=)
ES (1) ES2242222T3 (https=)
HU (1) HU228185B1 (https=)
ID (1) ID16512A (https=)
IL (1) IL122211A (https=)
MX (1) MX9709265A (https=)
NO (1) NO321984B1 (https=)
NZ (1) NZ329145A (https=)
PL (1) PL189696B1 (https=)
PT (1) PT835266E (https=)
TW (1) TW517061B (https=)
WO (1) WO1997036932A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
EP1717248A1 (en) 1997-06-04 2006-11-02 Oxford Biomedica (UK) Limited Tumor targeted vector
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
DE69837706T2 (de) * 1997-07-21 2008-01-10 Active Biotech Ab Zytolyse der geeigneten zielzellen mit superantigen konjugate mittels der induktion von t-zell aktivierung
US6872394B1 (en) 1997-12-02 2005-03-29 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
WO1999027889A2 (en) * 1997-12-02 1999-06-10 Idaho Research Foundation, Inc. Non-toxic immune stimulating enterotoxin compositions
CA2338184A1 (en) * 1998-08-13 2000-02-24 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
US7491402B2 (en) * 1998-12-24 2009-02-17 Auckland Uniservices Limited Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
JP2004515479A (ja) * 2000-12-04 2004-05-27 オークランド ユニサーヴィスィズ リミテッド 免疫調節性構築物およびその使用
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
AU2003245182A1 (en) * 2002-05-09 2003-11-11 Auckland Uniservices Limited Streptococcal superantigens spe-l and spe-m
NZ519371A (en) * 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
JP2008520227A (ja) * 2004-11-18 2008-06-19 メディジーン リミテッド 可溶性二官能性タンパク質
WO2006105168A2 (en) * 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Enhancing immune responses with bacterial exotoxins
US20070178113A1 (en) * 2005-11-22 2007-08-02 Backstrom B T Superantigen conjugate
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PT3010535T (pt) * 2013-06-19 2020-07-03 Integrated Biotherapeutics Inc Péptidos de toxoide derivados de modulina solúvel em fenol, delta toxina, superantigénios e suas fusões
MX371328B (es) * 2013-08-30 2020-01-27 Aprilbio Co Ltd Constructo de fusion de la fraccion efectora del fragmento de union a antigeno (fab) de anti-albumina de suero y su metodo de preparacion.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
WO2019023341A1 (en) 2017-07-27 2019-01-31 Integrated Biotherapeutics, Inc. IMMUNOGENIC COMPOSITION COMPRISING A MELTING PEPTIDE DERIVED FROM TOXOIDS OF SUPERANTIGENES
US12188063B2 (en) 2019-02-08 2025-01-07 Institute Of Science Tokyo Enzymatic mutant suitable for homogeneous immunoassay method
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
EP4598588A1 (en) * 2022-10-05 2025-08-13 Musc Foundation for Research Development Superantigen vaccine conjugate for the treatment of cancer

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627644A (en) 1968-03-01 1971-12-14 Hajime Okamoto Process for the cultivation of hemolytic streptococci
US3903262A (en) * 1972-03-13 1975-09-02 Cutter Lab Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
GB1587244A (en) 1977-07-01 1981-04-01 Memm Spa Streptococcal antigen pharmaceutical compositions containing it and its use in medical diagnosis and treatment
US4268434A (en) 1979-01-09 1981-05-19 Higerd Thomas B Immunosuppressive extracellular product from oral bacteria
US5091091A (en) 1981-11-06 1992-02-25 Terman David S Protein A perfusion and post perfusion drug infusion
US4699783A (en) 1983-03-11 1987-10-13 Terman David S Products and methods for treatment of cancer
US4681870A (en) 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
FR2589267B1 (fr) 1985-10-25 1991-05-31 Bertin & Cie Procede de traitement d'images, notamment dans une installation de tri postal
US4980160A (en) 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
ES2058538T3 (es) 1988-07-22 1994-11-01 Imre Corp Compuestos de proteina a purificados y procedimiento para su preparacion.
DE3921211C1 (https=) 1989-06-28 1990-11-29 Idt Ag Fuer In Vivo Diagnostik Und Therapie, Zuerich, Ch
SE8903100D0 (sv) 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
US6042837A (en) 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6126945A (en) 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
CA2078003C (en) 1990-01-17 2006-11-21 David S. Terman Tumor killing effects of enterotoxins and related compounds
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
US5858363A (en) 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
DK0610179T3 (da) 1990-07-20 1997-03-24 Pharmacia & Upjohn Ab Målspecifikke antistof-superantigenkonjugater og fremstilling deraf
WO1993024136A1 (en) 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
WO1993014634A1 (en) 1992-01-28 1993-08-05 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US5545716A (en) 1992-09-08 1996-08-13 University Of Florida Superantigen agonist and antagonist peptides
US5519114A (en) 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
SE9402430L (sv) * 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
JPH11514844A (ja) 1995-06-07 1999-12-21 リージェンツ オブ ザ ユニバーシティー オブ ミネソタ 連鎖球菌毒素ａの突然変異体および使用方法
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
AU2429397A (en) 1996-03-29 1997-10-22 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
BR9714641A (pt) 1996-12-06 2002-01-22 Univ Minnesota Mutantes de toxina a de estreptococo e métodos de uso
AU734597B2 (en) 1996-12-06 2001-06-21 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
US6774218B2 (en) 1996-12-06 2004-08-10 Regents Of The University Of Minnesota Mutants of streptococcal toxin C and methods of use
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
IL119938A (en) 1996-12-30 2005-08-31 Yissum Res Dev Co Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20010046501A1 (en) 2000-03-14 2001-11-29 Johnson Howard M. Superantigen enhancement of specific immune responses
JP4283430B2 (ja) 2000-09-26 2009-06-24 株式会社カネカ エンテロトキシンの吸着材、吸着除去方法および吸着器
JP2004515479A (ja) 2000-12-04 2004-05-27 オークランド ユニサーヴィスィズ リミテッド 免疫調節性構築物およびその使用
CN1369550A (zh) 2001-02-16 2002-09-18 沈阳协合集团有限公司 一种金黄色葡萄球菌的培养物及其制备方法
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy

Also Published As

Publication number Publication date
TW517061B (en) 2003-01-11
US7226595B2 (en) 2007-06-05
IL122211A (en) 2009-07-20
CZ371297A3 (cs) 1998-05-13
NZ329145A (en) 2000-06-23
MX9709265A (es) 1998-03-31
HUP9903444A2 (hu) 2000-02-28
DE69733179D1 (de) 2005-06-09
AU707827B2 (en) 1999-07-22
PL189696B1 (pl) 2005-09-30
IL122211A0 (en) 1998-04-05
PT835266E (pt) 2005-07-29
HUP9903444A3 (en) 2003-08-28
NO975435D0 (no) 1997-11-26
DE69733179T2 (de) 2005-10-06
AU2525197A (en) 1997-10-22
EP0835266A1 (en) 1998-04-15
WO1997036932A1 (en) 1997-10-09
CA2222757C (en) 2011-07-26
CA2222757A1 (en) 1997-10-09
CZ294475B6 (cs) 2005-01-12
NO975435L (no) 1998-01-29
PL323626A1 (en) 1998-04-14
BR9702179A (pt) 1999-03-16
ID16512A (id) 1997-10-02
US20030092894A1 (en) 2003-05-15
EP0835266B1 (en) 2005-05-04
JP4114951B2 (ja) 2008-07-09
ES2242222T3 (es) 2005-11-01
HU228185B1 (en) 2013-01-28
ATE294818T1 (de) 2005-05-15
JP2002502363A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
NO321984B1 (no) Konjugat, fremstilling, samt anvendelse derav
US6514498B1 (en) Modified/chimeric superantigens and their use
US20250041409A1 (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
JP6514774B2 (ja) 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用
US7074909B2 (en) Antibodies
AU2013271428B2 (en) Human bispecific EGFRvIII antibody engaging molecules
NO320151B1 (no) Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre
AU2014287244A1 (en) Certain improved human bispecific EGFRvIII antibody engaging molecules
Antonsson et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR
Riccio et al. T-cell activating tribodies as a novel approach for efficient killing of ErbB2-positive cancer cells
WO2024051223A1 (zh) 药物组合及用途
CN113396159B (zh) 人抗antxr嵌合抗原受体及其用途
CN115304680A (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
US20070161080A1 (en) Antibodies
CN103374071B (zh) 一种抗derlin‑1人源化抗体的制备

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees